MAP Pharmaceuticals Reports Second Quarter of 2010 Financial Results

Tuesday, August 3, 2010 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

MAP PHARMACEUTICALS, INC.

(a development stage enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2010

2009

2010

2009

Collaboration revenue

$

-

$

8,645

$

-

$

16,129

Operating expenses:

   Research and development 

8,242

9,628

18,028

23,703

   Sales, general and administrative

3,910

3,437

7,791

6,245

   Total operating expenses

12,152

13,065

25,819

29,948

Loss from operations 

(12,152)

(4,420)

(25,819)

(13,819)

Other expense, net 

(337)

(549)

(728)

(1,070)

Net loss 

(12,489)

(4,969)

(26,547)

(14,889)

Net loss per share attributable to common  stockholders, basic and diluted

$

(0.47)

$

(0.24)

$

(1.01)

$

(0.72)

Weighted-average common shares used in  computing net loss per share attributable to  common stockholders, basic and diluted

26,480,166

20,699,343

26,167,861

20,641,878



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store